Literature DB >> 17391631

Current treatments in functional dyspepsia.

Meredythe A McNally, Nicholas J Talley.   

Abstract

By nature of the definition of functional dyspepsia (FD), organic causes have to be ruled out before therapy can be directed. However, in uninvestigated dyspepsia in the absence of alarm features, Helicobacter pylori "test and treat" or an empiric trial of acid suppression therapy for 4 to 8 weeks is reasonable. If alarm symptoms or signs are present, or if the dyspepsia symptoms first occur in those aged greater than 55 years, prompt esophagogastroduodenoscopy is mandatory to exclude serious disease and positively diagnose FD. Empiric acid suppression with H(2)-receptor antagonists or proton-pump inhibitors is superior to placebo in treatment of FD, but those patients with meal-related symptoms are least likely to respond. Helicobacter pylori eradication in FD benefits a minority of cases but is worthwhile, as response may be maintained. There is increasing evidence that some prokinetics may be superior to placebo in treatment of FD, but probably only a minority respond; those with meal-related symptoms may have the best response. Antidepressant therapy may have a place in management of difficult cases, but adequate randomized controlled trials are unavailable.

Entities:  

Year:  2007        PMID: 17391631     DOI: 10.1007/s11938-007-0068-1

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  60 in total

Review 1.  Management of nonulcer dyspepsia.

Authors:  R S Fisher; H P Parkman
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

2.  Effect of tegaserod on gut transit in male and female subjects.

Authors:  L Degen; C Petrig; D Studer; S Schroller; C Beglinger
Journal:  Neurogastroenterol Motil       Date:  2005-12       Impact factor: 3.598

3.  Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.

Authors:  J Tack; S J Middleton; M C Horne; H Piessevaux; J S Bloor; N L Meyers; R M J Palmer
Journal:  Aliment Pharmacol Ther       Date:  2006-06-01       Impact factor: 8.171

Review 4.  Functional gastroduodenal disorders.

Authors:  Jan Tack; Nicholas J Talley; Michael Camilleri; Gerald Holtmann; Pinjin Hu; Juan-R Malagelada; Vincenzo Stanghellini
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

5.  Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia.

Authors:  C Feinle; O Meier; B Otto; M D'Amato; M Fried
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

Review 6.  An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews.

Authors:  Paul Moayyedi; Jon Deeks; Nicholas J Talley; Brendan Delaney; David Forman
Journal:  Am J Gastroenterol       Date:  2003-12       Impact factor: 10.864

7.  Empirically derived symptom sub-groups correspond poorly with diagnostic criteria for functional dyspepsia and irritable bowel syndrome. A factor and cluster analysis of a patient sample.

Authors:  G D Eslick; S C Howell; J Hammer; N J Talley
Journal:  Aliment Pharmacol Ther       Date:  2004-01-01       Impact factor: 8.171

8.  Role of tension receptors in dyspeptic patients with hypersensitivity to gastric distention.

Authors:  Jan Tack; Philip Caenepeel; Maura Corsetti; Jozef Janssens
Journal:  Gastroenterology       Date:  2004-10       Impact factor: 22.682

9.  A placebo-controlled trial of itopride in functional dyspepsia.

Authors:  Gerald Holtmann; Nicholas J Talley; Tobias Liebregts; Birgit Adam; Christopher Parow
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245

Review 10.  Review article: functional dyspepsia--should treatment be targeted on disturbed physiology?

Authors:  N J Talley
Journal:  Aliment Pharmacol Ther       Date:  1995-04       Impact factor: 8.171

View more
  1 in total

1.  Evaluation of Helicobacter pylori eradication and drug therapy in patients with functional dyspepsia.

Authors:  Weidong Zhao; Xiaoqin Zhong; Xinying Zhuang; Hongmei Ji; Xinxin Li; Anqing Li; Ruicai Wang; Jianyou Zhu; Yanqing Li
Journal:  Exp Ther Med       Date:  2013-05-13       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.